Pfizer: Sasanlimab in Combination With Bcg Improves Event-Free Survival in Patients With Bcg-Naïve, High-Risk Nonmuscle Invasive Bladder Cancer
辉瑞:Sasanlimab与Bcg联合使用提高了BCG初治、高风险非肌肉侵袭性膀胱癌患者的无事件生存率
Pfizer: Sasanlimab in Combination With Bcg Improves Event-Free Survival in Patients With Bcg-Naïve, High-Risk Nonmuscle Invasive Bladder Cancer
辉瑞:Sasanlimab与Bcg联合使用提高了BCG初治、高风险非肌肉侵袭性膀胱癌患者的无事件生存率
使用浏览器的分享功能,分享给你的好友吧